NEW YORK, May 10, 2019 /PRNewswire/ -- Lyfebulb, a chronic
disease-focused, patient-empowerment platform that connects
patients with industry to support user-driven innovation, and
Celgene Corporation (NASDAQ: CELG) announced the 10 finalists
chosen for the Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS:
An Innovation Challenge."
The following finalists will compete at the Innovation Challenge
Summit on June 13, 2019, for a
$25,000 monetary grant to further
develop their proposed innovations:
- Abilitech Medical, Shawna
Persaud: Medical device intended to help people with MS with
mobility challenges use their arms
- AXS Map, Jason DaSilva: Web
platform that allows users to locate, rate and review the
accessibility of any location in the world
- BeCareLink, Alan Gilbert:
Predictive artificial intelligence (AI) digital therapeutics
platform which remotely measures clinically validated assessments
of cognition and motion to help improve quality of care and reduce
costs for people with MS
- C. Light Technologies, Inc, Zachary
Helft: Neurotech and AI technology using eye motion measured
on the cellular scale to monitor disease state in people with MS
for treatment efficacy feedback
- Dance4Healing, Amy Li:
AI-powered telehealth live video platform which brings community,
exercise and physical rehabilitation into the home to encourage
healthy behavior change
- Icometrix, Wim Van Hecke:
AI-based brain imaging solutions to monitor disease
progression
- Leoplus USA, Kinza Kasher: Device and app which aims to
support communications between patients and care partners
- Loro co., David Hojah: Socially assistive companion robot for
people with mobility challenges
- Moodify, Kate Milliken:
Web-based tool which builds communities, aims to reduce loneliness,
creates searchable content moments and tracks the emotional
journey
- ThermApparel LLC, Bradley Dunn:
Lightweight, comfortable and concealable cooling apparel for people
with extreme heat sensitivity
"At Lyfebulb, we build communities of patients with chronic
disease around a message of inspiration and hope for the future.
Each of these patient entrepreneurs is inspirational, as they have
taken their frustrations of living with their disease – or
observing it in a loved one – and are working to turn those
insights into business solutions to help members of the MS
community live their daily lives more comfortably," said Dr.
Karin Hehenberger, CEO and Founder
of Lyfebulb.
These finalists are being recognized as outstanding patient
entrepreneurs – those who have been affected by MS as either a
patient, loved one or support partner – whose companies are helping
develop solutions to address an unmet need in MS. A "pitch session"
will be held at the Challenge Summit, and a winner will be chosen
by a diverse group of experts in the MS, healthcare and business
communities. The panel of judges will include:
- Tim Coetzee, PhD: Chief
Advocacy, Services and Research Officer, National Multiple
Sclerosis Society;
- Adam Fine: General Partner and
CEO, Windham Venture Partners;
- Elizabeth Jones: MS Patient
Ambassador;
- Darin T. Okuda, MD, MS, FAAN,
FANA: Director, Neuroinnovation Program, Multiple Sclerosis &
Neuroimmunology Imaging Program, UT Southwestern Medical Center;
and
- Deneen Vojta, MD: Executive Vice
President, Global Research & Development, UnitedHealth
Group.
"We are excited to bring together these patient entrepreneurs,
judges and members of the Celgene and Lyfebulb teams for an
engaging and interactive summit," said Terrie Curran, President, Celgene Inflammation
and Immunology. "Ultimately, we hope to foster discussion about
ways to advance innovation in the space and look forward to
awarding this grant that will help support people with MS and their
families."
About Multiple Sclerosis
Multiple sclerosis (MS) is a
chronic, often debilitating disease that affects approximately
2.5 million people worldwide. In MS, an abnormal response of
the body's immune system causes inflammation and damage to
myelin—the substance covering nerve fibers—in addition to damage to
nerves themselves. Signs and symptoms are varied and can pose
significant challenges in daily life.
About Lyfebulb
Lyfebulb is a chronic disease-focused,
patient empowerment platform that connects patients and industry
(manufacturers and payers) to support user-driven innovation.
Lyfebulb promotes a healthy, take-charge lifestyle for those
affected by chronic disease. Grounded with its strong foundation in
diabetes, the company has expanded disease states covered into
cancer, inflammatory bowel disease, multiple sclerosis, and
depression/anxiety.
See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin
Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About Celgene
Celgene Corporation, headquartered in
Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest, LinkedIn,
Facebook and YouTube.
For inquiries, please contact:
Lyfebulb:
Karin
Hehenberger, 917-575-0210
CEO and Founder
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lyfebulb-and-celgene-announce-finalists-for-2019-addressing-unmet-needs-in-ms-an-innovation-challenge-300847831.html
SOURCE Lyfebulb